Jam

Provident Financial Holdings (NASDAQ: PROV) announced a quarterly cash dividend of $0.14 per share. Shareholders of record on November 13, 2025, will receive the dividend, payable on December 4, 2025. The company’s decision reflects confidence in its financial position and commitment to shareholder returns.

Archrock, Inc. (NYSE: AROC) declared a quarterly cash dividend of $0.145 per common share, payable May 15, 2024, to holders of record on May 7, 2024. This reflects Archrock’s financial stability and commitment to shareholder value amid evolving energy market dynamics. The company’s focus on efficient operations, advanced compression technologies, and sustainable solutions, including exploring alternative power sources, supports its long-term business model and resilience in a capital-intensive industry. Investors are monitoring Archrock’s strategies to balance returns with innovation and sustainability investments.

Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics, debuted as a top employer in *Science* magazine’s survey, ranking second. The company excelled in innovation, values alignment, employee loyalty, and respect. This recognition coincides with Ionis’ progress in RNA therapeutics, developing antisense oligonucleotides for diseases like spinal muscular atrophy. CEO Brett Monia credits the company’s success to its people and culture, while Eric Swayze emphasizes their patient-centric approach. Ionis faces increasing competition in the RNA therapy market but aims to maintain its leadership through continued innovation and talent retention.

Alcon and STAAR Surgical announced the postponement of STAAR’s Special Meeting of Stockholders regarding their proposed merger. Originally scheduled for October 23, 2025, it’s now set for November 6, 2025. The record date for voting eligibility remains September 12, 2025. The merger aims to strengthen Alcon’s refractive surgery market position through STAAR’s ICL technology. Analysts suggest regulatory reviews and due diligence contributed to the delay. The combined entity anticipates innovation in intraocular lens technology but faces integration challenges and market competition.

Jeep launched a social media campaign featuring comedian Iliza Shlesinger to promote the 2026 Grand Wagoneer. The “Family SUV” campaign, created with Highdive, humorously highlights the vehicle’s spaciousness, comfort, and safety features. Shlesinger parodies traditional vehicle reveals in the video, now on YouTube, with shorter clips on other platforms. The 2026 Grand Wagoneer, starting under $65,000, aims for family-friendliness with added value.

VSee Health (NASDAQ:VSEE) announced on October 23, 2025, record revenue growth and the elimination of over $5 million in legacy SPAC debt. This strengthens the company’s balance sheet, boosts creditor confidence, and aids NASDAQ listing compliance. Management highlighted shareholder support and views this as positioning VSee Health for sustained long-term growth. The company aims to capitalize on the telehealth sector’s expansion with its scalable, API-driven platform.

Ermenegildo Zegna N.V. reported a 2.3% YoY decrease in revenue for 9M 2025, totaling €1,325.9 million. Q3 2025 revenues, however, grew slightly by 0.2% YoY to €398.2 million, with a 3.6% organic increase. DTC channel sales rose 4.5% YoY (9.1% organic), while wholesale declined. Zegna brand led the growth, with Thom Browne experiencing a decline. The Americas region showed strong organic growth. The company anticipates a challenging environment due to consumer demand and currency fluctuations.

First Atlantic Nickel reported Phase 2X drilling results from the Pipestone XL Nickel Alloy Project. Drill hole AN-25-08 showed 480 meters averaging 1.35% Ni in magnetic concentrate, yielding 0.12% magnetically recoverable Ni over the interval. This doubled the drill-confirmed strike length to 800 meters within a 4-km target area. Testing also identified potentially recoverable Cr and Co byproducts. Further drilling eastward will optimize testing across the remaining target area, informed by a refined structural model.

Pharming Group will report its Q3 2025 financial results and provide a business update on November 6th. Investors will focus on Ruconest® performance amid competitive HAE therapies and Pharming’s ability to maintain market share. The update will detail R&D pipeline progress, strategic initiatives including collaborations/acquisitions, and capital allocation. Analysts anticipate insights into revenue growth, expense management, and pipeline advancement’s impact on investor sentiment and future prospects. Guidance on full-year performance and strategic priorities will also be closely watched.

Tamboran Resources announced the pricing of its stock offering of 2,324,445 shares at $21.00 per share, expected to close on October 24, 2025, pending standard conditions. The offering, managed by RBC Capital Markets, Wells Fargo Securities, and BofA Securities, anticipates gross proceeds of approximately $48.8 million. Tamboran plans to use the funds for its development plan in the Beetaloo Basin, working capital, and general corporate purposes. The Beetaloo Basin represents a significant natural gas resource for Australia but faces risks including price fluctuations and regulatory hurdles.